The most utilized ultrasound enhancing agent is approved for use in pediatric patients
Data on file, Lantheus.
See in
High DEF(INITY)™
A clearer echo.
A better treatment plan.
Your decisions have real-life consequences. High DEF(INITY)™, high-resolution echocardiograms help answer clinical questions and improve patient management.1
Your decisions have real-life consequences. High DEF(INITY)™, high-resolution echocardiograms help answer clinical questions and improve patient management.1
DEFINITY® (Perflutren Lipid Microsphere) is the most used, most studied, and most trusted diagnostic ultrasound enhancing agent in the US.2-4
IN THE US
4 OUT OF 5
contrast-enhanced echoes are performed with DEFINITY®2
INCLUDED IN OVER
3200
peer-reviewed publications3
MORE THAN
21 million
studies performed4
DEFINITY® produces high-quality, consistent, and reliable images5-8
Our advanced microbubble technology helps you see in High DEF(INITY)™ with proven safety and consistent quality from echo to echo.2,5,6
DEFINITY® RT:
Trusted DEFINITY® efficacy and safety with room temperature storage.2,5,9
The DEFINITY® Illuminate Series
This series includes several in-person and virtual peer-to-peer presentations delivered by healthcare professionals, as well as informational webinars and an operational efficiencies toolkit.
See how High DEF(INITY)TM provides value for your institution
Demonstrated across gender, race, and age2
Facts about how DEFINITY® works
Real-world experiences
What is DEFINITY®?
DEFINITY® is a diagnostic ultrasound enhancing agent that opacifies the left ventricular chamber and improves the delineation of the left ventricular endocardial border in patients with suboptimal echocardiograms.5
Move the slider to see in High DEF(INITY)™
DEFINITY®
Unenhanced
To avoid potential patient risks and institutional complexities, DEFINITY® does not contain these ingredients5:
- Iodine
- Radioactive materials
- Gadolinium
- Sulfur components
- Blood products
Sign up for DEFINITY® updates and announcements
Order DEFINITY® products
Know your suboptimal echo rate.
Ask about the IMPROVE program.
Ask about the IMPROVE program.
References:
-
Kurt M, Shaikh KA, Peterson L, et al. Impact of contrast echocardiography on evaluation of ventricular function and clinical management in a large prospective cohort. J Am Coll Cardiol. 2009;53(9):802-810.
-
Data on file, Lantheus.
-
Embase and Medline Search, May 2018; Data on file, Lantheus.
-
©2021 Millennium Research Group, Inc. All rights reserved. Reproduction, distribution, transmission or publication is prohibited. Reprinted with permission.
-
DEFINITY® [package insert]. N. Billerica, MA: Lantheus, Inc.
-
Sboros V, Moran CM, Pye SD, McDicken WN. Contrast agent stability: a continuous B-mode imaging approach. Ultrasound Med Biol. 2001;27(10):1367-1377.
-
Sonne C, Xie F, Lof J, et al. Differences in definity and optison microbubble destruction rates at a similar mechanical index with different real-time perfusion systems. J Am Soc Echocardiogr. 2003;16(11):1178-1185.
-
Kitzman DW, Goldman ME, Gillam LD, Cohen JL, Aurigemma GP, Gottdiener JS. Efficacy and safety of the novel ultrasound contrast agent perflutren (definity) in patients with suboptimal baseline left ventricular echocardiographic images. Am J Cardiol. 2000;86(6):669-674.
-
DEFINITY® RT [package insert]. N. Billerica, MA: Lantheus, Inc.
INDICATIONS
DEFINITY® is indicated, after activation, for use in adult and pediatric patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.
IMPORTANT SAFETY INFORMATION
WARNING: SERIOUS CARDIOPULMONARY REACTIONS
Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren-containing microsphere administration. Most serious reactions occur within 30 minutes of administration.
- Assess all patients for the presence of any condition that precludes DEFINITY® administration [see Contraindications (4)].
- Always have resuscitation equipment and trained personnel readily available [see Warnings and Precautions (5.1)].
References:
- Kurt M, Shaikh KA, Peterson L, et al. Impact of contrast echocardiography on evaluation of ventricular function and clinical management in a large prospective cohort. J Am Coll Cardiol. 2009;53(9):802-810.
- Data on file, Lantheus.
- Embase and Medline Search, May 2018; Data on file, Lantheus.
- ©2021 Millennium Research Group, Inc. All rights reserved. Reproduction, distribution, transmission or publication is prohibited. Reprinted with permission.
- DEFINITY® [package insert]. N. Billerica, MA: Lantheus, Inc.
- Sboros V, Moran CM, Pye SD, McDicken WN. Contrast agent stability: a continuous B-mode imaging approach. Ultrasound Med Biol. 2001;27(10):1367-1377.
- Sonne C, Xie F, Lof J, et al. Differences in definity and optison microbubble destruction rates at a similar mechanical index with different real-time perfusion systems. J Am Soc Echocardiogr. 2003;16(11):1178-1185.
- Kitzman DW, Goldman ME, Gillam LD, Cohen JL, Aurigemma GP, Gottdiener JS. Efficacy and safety of the novel ultrasound contrast agent perflutren (definity) in patients with suboptimal baseline left ventricular echocardiographic images. Am J Cardiol. 2000;86(6):669-674.
- DEFINITY® RT [package insert]. N. Billerica, MA: Lantheus, Inc.
Customer Service 1.800.299.3431
BACK TO TOP